The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade)

Rheumatology
Gisela KobeltJ Braun

Abstract

In the past, treatment options for ankylosing spondylitis (AS) have been limited, and the introduction of new treatments such as infliximab will have a noticeable impact on health-care budgets. The objective of this study was therefore to assess the current burden of the disease and estimate the cost-effectiveness of infliximab treatments. A cross-sectional retrospective observational study of resource consumption and utility related to disease severity was performed in patients who had participated in a population survey between 1992 and 1994 at the University of Bath and patients regularly followed at the Royal National Hospital for Rheumatic Diseases in Bath for up to 9 years. Mean costs and utility were estimated using a regression model including age, gender, disease duration, disease activity and functional status, and disease development was expressed as annual progression of functional disability. Cost-effectiveness of infliximab was modelled using a 3-month placebo-controlled clinical trial with open 1-yr extension in 70 patients, over a total time frame of 2 yr. In the model, costs and utility controlled for disease severity and age from the observational study were assigned to individual patients. The effect of long-...Continue Reading

Citations

Jun 2, 2006·Springer Seminars in Immunopathology·Burkhard Möller, Peter M Villiger
Jun 30, 2009·Rheumatology International·L Goh, A Samanta
Jan 15, 2013·Rheumatology International·Alena PetříkováJozef Kolář
Jun 21, 2007·International Journal of Technology Assessment in Health Care·Gisela KobeltJürgen Braun
May 22, 2008·Rheumatology·D J PradeepK Gaffney
Mar 23, 2011·Rheumatology·Andrew KeatB Paul Wordsworth
Jun 28, 2013·Rheumatology·Emma HaglundIngemar F Petersson
Aug 30, 2005·Annals of the Rheumatic Diseases·J ZochlingUNKNOWN European League Against Rheumatism
Oct 22, 2005·Annals of the Rheumatic Diseases·J Sieper, M Rudwaleit
Oct 22, 2005·Annals of the Rheumatic Diseases·A Kavanaugh
Oct 14, 2006·Annals of the Rheumatic Diseases·M Drummond
May 28, 2005·Current Rheumatology Reports·Walter P Maksymowych
Jul 28, 2005·Current Rheumatology Reports·Sonja Merkesdal, Henning Zeidler
Apr 20, 2005·Current Opinion in Rheumatology·Allen Anandarajah, Christopher T Ritchlin
Jun 16, 2005·Current Opinion in Rheumatology·Jane Zochling, Jürgen Braun
Apr 1, 2005·Expert Review of Pharmacoeconomics & Outcomes Research·Annelies Boonen, Désirée van der Heijde
Jul 21, 2012·Expert Review of Pharmacoeconomics & Outcomes Research·Timm D KirchhoffSonja Merkesdal
Jan 13, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Krzysztof Piotr Malinowski, Paweł Kawalec
Jul 30, 2005·Expert Opinion on Biological Therapy·M Rudwaleit, J Sieper
Nov 1, 2007·Current Medical Research and Opinion·Jeroen P JansenElke Hunsche
Apr 17, 2012·Reumatología clinica·Vega JovaniUNKNOWN en representación del Grupo de estudio emAR
Nov 3, 2010·Best Practice & Research. Clinical Rheumatology·Annelies Boonen, Walter P Maksymowych
Sep 18, 2007·Best Practice & Research. Clinical Rheumatology·Arthur Kavanaugh
Apr 7, 2007·Rheumatic Diseases Clinics of North America·Philip Mease
Mar 1, 2006·Rheumatic Diseases Clinics of North America·Arthur Kavanaugh
Jun 9, 2005·International Journal of Dermatology·Mohanad BaklehElie F Berbari
Oct 23, 2012·International Journal of Rheumatic Diseases·Leslie Goh, Ash Samanta
Mar 13, 2014·International Journal of Rheumatic Diseases·Amal Abdul-Sattar, Sahar Abou El Magd
Jun 9, 2016·Revista Brasileira De Reumatologia·Valderilio Feijó AzevedoDenizar V Araújo
Jun 17, 2006·Best Practice & Research. Clinical Rheumatology·Jan BrandtPaul Emery
Jun 22, 2005·Journal of the American Academy of Dermatology·Alice B Gottlieb
Mar 20, 2013·International Journal of Rheumatology·Onur BaserAkif Altinbas
Sep 1, 2004·Expert Opinion on Drug Safety·Roy M FleischmannRichard L Stern
Oct 6, 2004·Expert Opinion on Pharmacotherapy·Kim A Papp
Jun 21, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Allan WailooStefan Siebert

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.